RxDoctor Payments Data

Courtney Davis, APRN

Family · Glasgow, KYNPI 1790406528

Payments from drug & device makers

$1,251in general payments, 2019–2025

Across 43 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$246
  • Vanda Pharmaceuticals Inc.$234
  • AbbVie$225
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$206
  • Novo Nordisk$133
  • Axsome Therapeutics, Inc.$110
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$1,251100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,251 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,650
Medicare patients
95
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$48,650
OzempicSemaglutide38$41,339
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,738
TrintellixVortioxetine Hydrobromide17$9,971
AirsupraAlbuterol Sulfate/Budesonide13$7,026
LinzessLinaclotide13$6,590
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,983
Albuterol Sulfate HfaAlbuterol Sulfate36$1,621
Memantine Hcl ErMemantine Hcl17$902
NitrofurantoinNitrofurantoin Macrocrystal18$529
Omega-3 Acid Ethyl Esters12$495
Ondansetron OdtOndansetron24$456
Omeprazole37$435
Esomeprazole Magnesium25$428
Gabapentin45$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$43$48,65044 claims
Novo NordiskOzempic$133$41,33938 claims
AstraZenecaBreztri Aerosphere, Airsupra$246$26,76439 claims
AbbVieLinzess$225$6,59013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →